India has been long called the "Pharmacy of the World" for because it works hard to make generic drugs cheap for people all over the world. On the other hand, the Union Budget 2026–27 is a strong attempt to change that. Thanks to the ₹10 crore Biopharma SHAKTI project, the Indian government wants to stop copying existing medicines and start making their own. 

This change is being made because it is now known that the old method of making many generic drugs with small profits does not work anymore. Currently, biologics and biosimilars represent the most promising medical and business opportunities globally. These complex drugs combat cancer, diabetes, and other non-transmissible diseases. These medicines are more profitable but harder to develop, test, and make because they are made from living cells instead of pills.

What the industry refers to as the "Valley of Death" lies at the heart of the issue addressed by the budget. Simply put, this is the stage at which a promising medicine discovery dies in the lab before reaching patients due to a lack of funding. Clinical trials are costly, time-consuming, and risky, and many Indian ideas have already failed at this stage. The Biopharma SHAKTI fund, which is spread over five years, is intended to bridge this gap by sharing financial risk and giving companies confidence to invest in original research. 

Dr Saloni Wagh, MD of Supriya Lifescience Ltd, sees the approach as a sign of policy maturity. "The ₹10,000 crore commitment signals a clear recognition that global leadership requires sustained investment in research capability, clinical trial infrastructure and manufacturing depth, rather than short-term incentives," she told reporters. 

A major pillar of the strategy is the expansion of India’s clinical trial ecosystem. The budget calls for more than 1,000 certified clinical trial sites around the country, effectively transforming India into a huge, multi-center research hub. For patients, this might imply faster access to new treatments. For the sector, it reduces development schedules and costs, making India more appealing to global pharmaceutical partners. 

Regulatory reform is another critical component. Indian authorities intend to analyse data concurrently rather than sequentially by implementing "concurrent review" methods similar to those used by the US Food and Drug Administration and the European Medicines Agency. In practice, this might reduce approval timelines by years while maintaining safety. 

Apurv Modi, Managing Director and Co-Founder of the Abhay Group, stated that the budget strikes a balance between innovation and access. "By launching the Biopharma Shakti initiative and exempting customs duty on critical drugs, the government is directly addressing both innovation and affordability in healthcare," he said. 

In addition to laboratories and factories, the budget considers individuals. Over the next five years, the government intends to fund the training of around 2.5 lakh specialised workers, including allied health professionals and multiskilled carers. This standardised workforce is regarded as critical for scaling hospitals, home-care services, and clinical research in a consistent and dependable manner. 

Another prominent movement is for medical tourism and traditional medicine. Five regional medical hubs are planned through public-private partnerships, and AYUSH pharmacies and drug testing facilities will be modernised to meet global pharmacopoeia standards. The goal is to position Ayurveda not only as a cultural tradition but also as a scientifically validated export industry. 

Shafiulla Hirehal Nuruddin, founder and managing director of Greenspace Herbs, praised the focus. He stated that by strengthening testing facilities and promoting evidence-based research through the WHO Global Traditional Medicine Centre, Ayurveda will gain the validation it requires to develop internationally. 

For regular individuals, the questions are practical: will medications become more affordable, will India develop its own cancer therapies, and will science graduates find jobs? The budget does not offer immediate solutions. What it does provide is a structural change away from scale-driven growth and toward innovation-led leadership. If successfully completed, India's gamble has the potential to reshape its role in global healthcare, not merely as a provider of drugs, but also as a source of innovative remedies.